Complexity – Handled.
Complexity – Handled.
Operationalize regulatory risk management to drive life sciences and healthcare success
In brief
Building digital trust and strategic advantage
with privacy and cybersecurity
01
Intro
Stay ahead of regulatory change with concise, actionable insights tailored to your sector.
Our In brief series distills the information that matters - so you can quickly understand the impact and what to do next.
Go in depth
Secondary button
02
What do you need to know?
The digital health sector is experiencing explosive growth.
You’ve been hacked. Now what?
Watch Véronique Barry explain the growing gap between digital health innovation and regulation - and how to navigate complexity as your technology evolves.
Go in depth
Secondary button
Read more about the ways attacks are evolving and how you can plan ahead
Go in depth
Secondary button
Read more about how the ways attacks are evolving and how you can plan ahead
03
Ones to watch: Regulatory themes to follow
Regulation in Canada is changing.
The evolution of these updates will impact pharmaceuticals, healthcare and life sciences overall — with nuanced differences depending on how your business is focused, structured and operating.
Check out the top regulatory themes to keep in mind now:
01
01
Pharmaceutical
Operating in this sector? Think about:
Pricing and high-risk retail management in a changing regulatory landscape
01
01
Biotechs and medtechs
Operating in this sector? Think about:
Navigating regulatory approvals in Canada amidst geopolitical volatility
01
01
Regulated health professionals
Operating in this sector? Think about:
Maintaining cross-jurisdictional compliance in a complex and rapidly changing regulatory environment
Increased scope of practice
01
01
Digital health
Operating in this sector? Think about:
Applying analogue legislation in a digital world and diverse Canadian population
Preparing for expected artificial intelligence legislation
The challenges of artificial intelligence and underlying data training sets
01
01
Private equity, venture capital, mergers and acquisitions
Operating in this sector? Think about:
Pricing and high-risk retail management in a changing regulatory landscape
Navigating regulatory approvals in Canada amidst geopolitical volatility
Maintaining cross-jurisdictional compliance in a matrixed regulatory environment
Applying analogue legislation in a digital world and diverse Canadian population
Maintaining regulatory compliance while cultivating a smooth entry (or exit)
Go in depth
Read more about supporting an effective privacy and cybersecurity plan to guide the organization in a changing risk landscape
Secondary button
Check out our at-a-glance regulatory view of the country.
Primary button
Secondary button
AU
HK
JP
CA
US
FR
DE
NL
GB
SG
ZA
UAE
04
IP at a regulatory crossroads
In the AI era, data abounds and it's growing by the day.
Innovative pharmaceutical companies must navigate effective regulatory IP protection with exposure to PMPRB price regulation. The chart below outlines key IP regimes available to life science companies in doing so.
Data protection
+
–
Purpose: To provide the manufacturer of an innovative drug a guaranteed minimum period of market exclusivity
Related to patent rights: No
Applicability: New chemical entity where the generation of the data supporting the approval required considerable effort
Term: 8 years of market exclusivity, potential for 6-month pediatric extension
+
Patent register listing
+
–
Purpose: To link the regulatory approval of a subsequent entry drug to the patent status of the drug to which a direct or indirect comparison or reference is made
Related to patent rights: Yes
Applicability: Medicines protected by patents that claim the medicinal ingredient, formulation, dosage form or use approved by a Notice of Compliance
Term: Until patent expiration, or patent removal from Patent Register
+
Certificates of supplementary protection (CSP)
+
–
+
Purpose: To provide an additional period of patent protection to partly compensate for term lost over time spent in research and obtaining marketing authorization
Related to patent rights: Yes
Applicability: Approved medicines containing a new medicinal ingredient, or a new combination of medicinal ingredients, protected by an eligible patent
Term: Up to 2 years after patent expiration
Patent term adjustment
+
–
+
Purpose: To compensate patentees for unreasonable delays in the processing of their patent applications by the Canadian Intellectual Property Office
Related to patent rights: Yes
Applicability: Patents with a filing date on or after December 1, 2020, issuing after the later of (i) the fifth anniversary of the “applicable day,” and (ii) the third anniversary of the day examination was requested
Term: Must be calculated, term runs concurrently with any CSP term
Patented medicine prices review board (PMPRB)
+
–
Purpose: To review prices of patented medicine to monitor for “excessive price”
Related to patent rights: Yes
Applicability: Invention that pertains to a medicine
Term: Until patent expiration
+
Go in depth
Read more about privacy programming
Secondary button
Here are three big ways privacy has changed and why it’s best addressed as a team sport:
Go in depth
Read more about privacy programming
Secondary button
05
The look-ahead: 2026 and beyond
Over the last 12 months, Canadian pharma companies saw a notable uptick in legal and regulatory developments.
What’s next on the radar for this core national industry?
Explore how regulation is likely to change pharma realities in the months and year ahead:
Go in depth
Read more about how federal and provincial regulation is changing.
Secondary button
Patentable subject matter
+
–
The Supreme Court will likely release its decision on the patentability of “methods of medical treatment” and dosage regimens in the first half of 2026.
+
Applying PMPRB guidelines
+
–
With the new PMPRB guidelines now in force, the first recommendations for hearings under the new guidelines may issue this year.
+
National pharmacare
+
–
+
The signing of bilateral agreements under the Pharmacare Act appears to have stalled since the federal election in April of 2025. It remains to be seen in 2026 whether the national pharmacare project will move forward or be repealed or reworked.
US most-favored-nation (MFN) prescription drug pricing
+
–
+
The global effects of the MFN drug pricing policy will continue to roll out in 2026 (our report here). Canadian pharma companies will need to grapple with dual forces to increase prices in response to this policy while maintaining compliance with price-lowering pressure in Canada under the PMPRB and pharmacare initiatives.
Drug regulation
+
–
After consulting on many new draft regulations and guidance in 2025 and early 2026, Health Canada may finalize some or all of these changes.
+
06
Toolbox tips: Construct governance by design
The best time to reinforce governance is before compliance slips through the cracks.
In light of so much regulation and regulatory change, pharma and life sciences companies will want to consider the following tips when refreshing — or reframing — risk through a proactive lens:
The best time to reinforce governance is before compliance slips through the cracks.
Go in depth
Read more about privacy programming
Secondary button
1
Define risk ownership and clarify processes for shared accountability
2
Talk about the balance point between proactive risk management and robust innovation at the senior management and board level
3
Create a rigorous means of continuously scanning for regulatory changes that could represent material risks
4
Establish a timeline for when regulatory updates and risk management will be addressed, how often, by whom, and how
Go in depth
Read more about privacy programming
Secondary button
For deeper insight into what this means for your business, explore our In depth series.
June 2026